Skip to main content
Clinical Trials/NCT01555398
NCT01555398
Completed
Phase 1

Open-label, Randomized Study to Evaluate the Effect of Food on the Pharmacokinetic Characteristics of Fenofibric Acid for HIP0901 Capsule in Healthy Male Subjects

Hanmi Pharmaceutical Company Limited1 site in 1 country48 target enrollmentFebruary 2012
ConditionsHealthy

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
Healthy
Sponsor
Hanmi Pharmaceutical Company Limited
Enrollment
48
Locations
1
Primary Endpoint
AUC of Fenofibric acid
Status
Completed
Last Updated
13 years ago

Overview

Brief Summary

The purpose of this study is to evaluate the effect of food on the pharmacokinetic characteristics of fenofibric acid for HIP0901 capsule.

Registry
clinicaltrials.gov
Start Date
February 2012
End Date
May 2012
Last Updated
13 years ago
Study Type
Interventional
Study Design
Crossover
Sex
Male

Investigators

Sponsor
Hanmi Pharmaceutical Company Limited
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Healthy male volunteers, age between 20 and 45
  • Informed of the investigational nature of this study and voluntarily agree to participate in this study
  • Weight\>50kg, BMI of \>18kg/m2 and \<27kg/m2 subject

Exclusion Criteria

  • Acute disease within 28 days prior to start of study drug administration
  • Use of any prescription medication within 14 days prior to Day 1
  • Use of any medication within 7 days prior to Day 1
  • Has a severe medical history of hypersensitivity to fibric acid derivative
  • Participation in another clinical study within 30 days prior to start of study drug administration

Outcomes

Primary Outcomes

AUC of Fenofibric acid

Time Frame: 0-96 hrs

Cmax of Fenofibric acid

Time Frame: 0-96 hrs

Study Sites (1)

Loading locations...

Similar Trials